Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2003 March;47(1) > The Quarterly Journal of Nuclear Medicine 2003 March;47(1):63-74

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  THERAPY RESPONSE IN NUCLEAR MEDICINE
Guest Editor: Bombardieri E.
FREEfree


The Quarterly Journal of Nuclear Medicine 2003 March;47(1):63-74

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Thallium-201 imaging in the assessment of tumor response to anti-tumor treatments

Berk F., Demir H., Aktolun C

Department of Nuclear Medicine, Kocaeli University, School of Medicine, Kocaeli, Turkey


FULL TEXT  


The advan­tag­es and lim­i­ta­tions of 201Tl imag­ing in assess­ing the ­tumor ­response to ­anti-can­cer ther­a­py are dis­cussed in ­this ­review. 201Tl has dis­tinc­tive advan­tag­es but ­more ­recent ­agents ­such as 99mTc ­MIBI and posi­tron emit­ters ­have ­some clin­i­cal super­ior­ities ­over 201Tl in ­this ­usage.

top of page

Publication History

Cite this article as

Corresponding author e-mail